Weight-loss doses are higher than diabetes doses
It also delays gastric emptying, inhibits glucagon release from pancreatic alpha cells, causes the proliferation of beta cells, and decreases their apoptosis
Lancet Diabetes Endocrinol 6(11):859869 Mann JFE, rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S et al (2017) Liraglutide and renal outcomes in type 2 diabetes
Some GLP-1 and dual incretin medicines already have approved uses in certain jurisdictions for type 2 diabetes, chronic weight management, or both
Talk to your provider if this is happening repeatedly
When used appropriatelymeaning clinically indicated patients taking FDA-approved formulations prescribed for them per medical guidelines while being monitored by a healthcare professionalthey have a well-characterized safety profile